Washington, August 7 the National Institutes of Health (NIH) has launched a clinical trial of the combination of antiviral drug radcivir and interferon – β – 1A in the treatment of new crown patients. < p > < p > redcivir is an antiviral drug developed by Gilead technology company in the United States. It was originally planned to treat Ebola hemorrhagic fever and Middle East respiratory syndrome. The U.S. Food and drug administration has previously issued an emergency use authorization, allowing U.S. medical institutions to “emergency use” radcivir when they treat severe patients with new crown. Interferon is an active protein with extensive antiviral and immunomodulatory effects produced by cells invaded by viruses or some bacteria. Laboratory studies have shown that interferon production is inhibited in some patients with new crowns. The aim of this randomized, double-blind, controlled trial was to verify the safety and efficacy of combination therapy with radcivir and interferon in the treatment of new crowns, the National Institutes of Health said in a statement. Interferon β – 1A used in the trial is a drug produced by Merck, a German pharmaceutical company, for the treatment of multiple sclerosis, which has been approved in more than 90 countries such as the United States. < / P > < p > according to the introduction, volunteers will be randomly assigned to receive a combination of radcivir and interferon beta-1a, and the other to receive radcivir and placebo. The two groups of volunteers received the same amount of radcivir intravenous injection, 200 mg on the first day, and then 100 mg daily for up to 10 days. At the same time, one group of volunteers will receive subcutaneous injection of 44 micrograms of interferon – β – 1A on days 1, 3, 5, and 7, respectively, and the other group will receive the same amount of placebo injection. The researchers will evaluate whether the combination therapy can shorten the time for patients to recover and leave hospital.